DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $84.41, for a total transaction of $300,499.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

John Lister also recently made the following trade(s):

  • On Friday, September 9th, John Lister sold 3,560 shares of DexCom stock. The stock was sold at an average price of $93.65, for a total transaction of $333,394.00.

Shares of DexCom Inc. (NASDAQ:DXCM) traded up 0.16% on Wednesday, reaching $82.02. 440,524 shares of the company’s stock traded hands. DexCom Inc. has a 52 week low of $47.92 and a 52 week high of $96.38. The company has a 50 day moving average of $90.14 and a 200-day moving average of $78.37. The stock’s market capitalization is $6.88 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.12. The firm earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. DexCom’s revenue for the quarter was up 47.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.05) earnings per share. Equities research analysts forecast that DexCom Inc. will post ($0.57) earnings per share for the current year.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

A number of equities research analysts have issued reports on DXCM shares. Jefferies Group reiterated a “buy” rating and set a $98.00 target price on shares of DexCom in a report on Wednesday, August 3rd. Benchmark Co. reduced their target price on shares of DexCom from $106.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, August 3rd. Deutsche Bank AG increased their target price on shares of DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, July 15th. Canaccord Genuity reiterated a “buy” rating and set a $95.00 target price on shares of DexCom in a report on Wednesday, July 13th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of DexCom in a report on Monday, June 20th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. DexCom currently has an average rating of “Buy” and an average target price of $95.08.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC increased its position in shares of DexCom by 59.3% in the second quarter. FMR LLC now owns 8,161,390 shares of the medical device company’s stock valued at $647,443,000 after buying an additional 3,036,821 shares during the period. Wellington Management Group LLP increased its position in shares of DexCom by 227.1% in the first quarter. Wellington Management Group LLP now owns 5,747,553 shares of the medical device company’s stock valued at $390,316,000 after buying an additional 3,990,578 shares during the period. Vanguard Group Inc. increased its position in shares of DexCom by 4.4% in the second quarter. Vanguard Group Inc. now owns 5,668,065 shares of the medical device company’s stock valued at $449,648,000 after buying an additional 238,974 shares during the period. Artisan Partners Limited Partnership increased its position in shares of DexCom by 22.0% in the second quarter. Artisan Partners Limited Partnership now owns 5,591,101 shares of the medical device company’s stock valued at $443,542,000 after buying an additional 1,008,260 shares during the period. Finally, Waddell & Reed Financial Inc. increased its position in shares of DexCom by 91.6% in the second quarter. Waddell & Reed Financial Inc. now owns 2,175,574 shares of the medical device company’s stock valued at $172,589,000 after buying an additional 1,040,279 shares during the period. Institutional investors and hedge funds own 99.37% of the company’s stock.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.